- Evaxion (EVAX, Financial) has launched a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS).
- GAS affects hundreds of millions globally, with severe complications like rheumatic heart disease and necrotizing fasciitis.
- EVAX's R&D pipeline now boasts eight vaccine candidates, leveraging AI-Immunology™ for accelerated development.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, has expanded its research and development pipeline by introducing EVX-B4, a novel vaccine program aimed at combating Group A Streptococcus (GAS). This bacteria is responsible for hundreds of millions of infections worldwide each year and can cause severe diseases, including rheumatic heart disease and necrotizing fasciitis. Currently, there is no preventive vaccine for GAS, underscoring the significant medical and commercial potential of EVX-B4.
Leveraging its AI-Immunology™ platform, Evaxion has successfully identified novel vaccine targets for GAS. This platform promises faster identification, design, and validation of targets, enabling quicker preclinical development for EVX-B4. The AI-driven approach offers significant advantages in the vaccine development space, potentially resulting in expedited time-to-market and reduced R&D costs.
The addition of EVX-B4 marks a significant milestone towards Evaxion's 2025 objectives, raising their total number of vaccine candidates to eight: five focusing on infectious diseases and three targeting cancer. This expansion aligns with Evaxion's partnership strategy, enhancing opportunities for out-licensing and strategic collaborations. The introduction of EVX-B4 follows an extensive evaluation process and expert consultations, highlighting a strategic and disciplined approach to pipeline growth.
